EP
EP3.F OraSure Technologies Inc
- Market cap
- EUR 220M
- P/E
- -
- P/B
- 0.75x
- ROE
- -12.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EP3.F undervalued?
Graham numberThe Graham number of OraSure Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OraSure Technologies Inc fundamental analysis
No fundamental analysis for OraSure Technologies Inc yet.
OraSure Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OraSure Technologies Inc
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid …
Full company profileOraSure Technologies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OraSure Technologies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 128M | 167M | 182M | 155M | 172M | 234M | 387M | 405M | 186M | 115M | 119M |
| Gross Profit | 88.0M | 99.0M | 114M | 94.6M | 102M | 118M | 148M | 172M | 79.4M | 48.2M | 52.1M |
| Operating Income | 20.3M | 27.7M | 28.4M | 7.80M | -6.28M | -11.6M | -6.04M | 43.4M | -23.9M | -68.1M | -70.1M |
| EBITDA | - | 34.1M | 35.7M | 15.5M | 3.44M | - | 10.3M | 64.4M | -13.6M | -58.2M | -61.2M |
| Net Income | 19.7M | 30.9M | 20.4M | 16.7M | -14.9M | -23.0M | -17.9M | 53.7M | -19.5M | -68.7M | -39.0M |
| EPS | - | 0.51 | 0.33 | 0.27 | -0.21 | -0.32 | -0.25 | 0.73 | -0.26 | -0.98 | -0.56 |
| Balance Sheet | |||||||||||
| Total Assets | 208M | 296M | 316M | 349M | 454M | 461M | 445M | 483M | 480M | 403M | 349M |
| Total Liabilities | 22.1M | 38.1M | 32.2M | 42.2M | 55.9M | 80.5M | 81.1M | 52.2M | 69.3M | 62.3M | 42.3M |
| Shareholders' Equity | 186M | 258M | 283M | 307M | 399M | 381M | 364M | 431M | 410M | 341M | 307M |
| Cash & Short-term Investments | 108M | 71.0M | 88.4M | 75.7M | 161M | 117M | 84.0M | 290M | 268M | 199M | 148M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 24.6M | 28.2M | 39.1M | 9.80M | 5.81M | -35.4M | -47.2M | 142M | 27.4M | -49.0M | -46.3M |
| Capital Expenditure | 4.35M | 4.34M | 6.34M | 9.31M | 26.7M | 48.1M | 63.9M | 10.3M | 3.80M | 4.20M | 6.69M |
| Free Cash Flow | - | 23.8M | 32.7M | 490K | -23.1M | -83.5M | -111M | 131M | 23.6M | -53.2M | -52.9M |
| Ratios | |||||||||||
| ROE | 10.6% | 12.0% | 7.2% | 5.4% | -3.7% | -6.0% | -4.9% | 12.5% | -4.8% | -20.2% | -12.7% |
| ROA | 9.5% | 10.4% | 6.5% | 4.8% | -3.3% | -5.0% | -4.0% | 11.1% | -4.1% | -17.0% | -11.1% |
| Net Profit Margin | 15.4% | 18.5% | 11.2% | 10.8% | -8.7% | -9.8% | -4.6% | 13.2% | -10.5% | -59.8% | -32.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
OraSure Technologies Inc dividends
OraSure Technologies Inc has not paid dividends in the last 9 fiscal years.
Who owns OraSure Technologies Inc
- Insiders 6.48%
- Institutions 88.66%
- Public & others 4.86%
- Shares outstanding 69.0M
- Free float 57.0M
OraSure Technologies Inc company profile
- Company name
- OraSure Technologies Inc
- Ticker
- EP3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 500
- Fiscal year end
- December
- Address
- 220 East First Street, Bethlehem, PA, United States, 18015
- Phone
- 610 882 1820
- Website
- orasure.com
About OraSure Technologies Inc
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
OraSure Technologies Inc management
10- Ms. Carrie Eglinton MannerPresident, CEO & Director · born 1975
- Mr. Kenneth J. McGrathChief Financial Officer · born 1972
- Ms. Michele AnthonySenior VP, Chief Accounting Officer, Controller & Assistant Secretary · born 1974
- Ms. Karen DaviesDiagnostics R&D & Chief Technologist
- Mr. Rafal Iwasiow Ph.D.Sample Management Solutions R&D & Chief Scientist
- Mr. Mike VallieVice President of Investor Relations
- Mr. Michael A. PollnerSenior VP, General Counsel & Corporate Secretary · born 1973
- Mr. David A. Rappaport C.F.A.Senior Vice President of Corporate Development, Strategy & Integration
- Ms. Amy SteigerwaltSenior Vice President of Human Resources
- Mr. Zachary WertSenior Vice President of Global Operations